Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

pembrolizumab 25Cyclophosphamide 20Nivolumab 13Doxorubicin 13Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Exercise 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Pemetrexed 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × (225)Ac-PSMA-617 × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡